Bruker Showcases Kit‑Enabled and Chromatography‑Free Workflows at MSACL to Accelerate Lab Efficiency

Billerica, MA – September 19, 2025 — Bruker Applied Mass Spectrometry (BAMS) today announced its participation at the MSACL conference in Montreal, where it will feature kit‑enabled workflows, including chromatography‑free options, designed to increase throughput, reduce complexity, and improve reproducibility in applied and clinical research laboratories. On the Bruker booth, solutions from PinPoint Testing LLC, RECIPE Chemicals + Instruments GmbH, and biocrates life sciences ag, each partly owned by Bruker, will be presented alongside the EVOQ^® DART-TQ⁺ (RUO) to demonstrate how standardized kits and turnkey methods can accelerate high‑quality results and streamline lab operations.

At MSACL, Bruker will highlight dual‑mode flexibility and performance on the EVOQ platform, supporting both conventional LC MS/MS and chromatography‑free DART-MS/MS for clinical research. Progress with RECIPE’s ClinDART^® workflows underscores the potential for ultra‑fast analysis, with completed results for 96 samples in under 40 minutes, while reducing operational burden and solvents by up to 95%. ClinDART RUO workflows and methods have been completed for antimycotics, antiepileptics, TCA, and single parameters like MPA and levetiracetam. In parallel, RECIPE’s ClinMass^® kits for LC MS/MS have been verified on the EVOQ^® DART-TQ⁺ for immunosuppressants, antibiotics, TCA, MMA, and MPA, with additional panels to follow, including antiepileptics, antidepressants, neuroleptics, and antimycotics, and an expanded pipeline for steroids, vitamins, and benzodiazepines.

The MxP^® Quant 1000 Kit from biocrates, now optimized and validated on the Bruker EVOQ^® DART-TQ⁺, enables quantitation of 1,233 metabolites (327 small molecules and 906 lipids) across 49 biochemical classes, with AI-driven processing and normalization in WebIDQ. The kit has been validated in human plasma and NIST reference samples to support multi‑site and longitudinal studies. PinPoint Testing will preview the DART ToxBox^® Oral Fluids Kit, designed for ISO 17025 Forensic Toxicology Labs, and showcase customizable DART MS/MS kits validated on EVOQ^® DART-TQ⁺ for RUO forensic screening across oral fluid, urine, and other matrices. Laboratories can now order a fully tested, pre‑validated workflow and kit covering everything from sample preparation to method implementation, enabling fast and confident adoption of DART methods. These kits cover benzodiazepines, stimulants, opioids, amphetamines, and cannabinoids, and are supported by Bruker’s Lab Accelerator Program, which delivers fully validated DART MS/MS workflows in four to six weeks.

“Across applied markets, laboratories are under pressure to do more with less, faster, and at a lower cost” said Jeffrey Zonderman, Senior Vice President, Bruker Applied Mass Spectrometry. “By combining Bruker’s EVOQ^® DART-TQ⁺ performance with validated, standardized kits from RECIPE, biocrates, and PinPoint Testing, we are helping customers simplify operations, increase throughput, and enhance reproducibility, all while reducing solvent consumption and downtime. These kit‑enabled workflows reflect our strategy to remove bottlenecks and bring high‑quality mass spectrometry results within reach for more labs. We are excited to collaborate with partners who share our commitment to speed, robustness, and data confidence for applied and clinical research.”

Looking ahead, Bruker and its partners plan to broaden verification and validation pipelines across additional ClinMass^® panels, expand ClinDART workflows where high throughput is critical, and advance forensic screening innovations with PinPoint’s DART ToxBox. Bruker will continue to invest in workflow standardization, cross‑platform confidence, and AI‑assisted data readiness, helping customers scale from pilot projects to multi‑site programs with confidence. MSACL attendees are invited to visit the Bruker booth to explore these solutions first‑hand and discuss implementation options tailored to their operational needs.

EVOQ^® DART-TQ⁺ and associated methods noted herein are for Research Use Only (RUO), not for use in clinical diagnostic procedures.